A prospective cohort study of Yindan Jiedu Granules for novel coronavirus infection (COVID-19) based on real-life medical settings

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2300070076

Enrollment

Unknown

Registered

2023-03-31

Start date

2023-04-01

Completion date

Unknown

Last updated

2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel coronavirus infection

Interventions

Application and non application of Yindan Jiedu Granules group:N/A

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: light and medium-sized patients who meet the definition of novel coronavirus infection (COVID-19) Patients;aged =18 years and =80 years;duration of disease = 5 days (at least 1/2 cases);no serious underlying disease, e.g. , tumor, renal failure;able to use a smartphone to complete the questionnaire;voluntarily participate in this study and sign the informed consent form

Exclusion criteria

Exclusion criteria: Pregnant or lactating women;Patients with known allergy to various components of the study drug

Design outcomes

Primary

Measure	Time frame
Disappearance time of single symptom;Chinese medicine evidence of efficacy;Disappearance rate of disease-related symptom clusters;Proportion of mild or moderate novel coronavirus infections converted to severe;Use of antipyretic and analgesic drugs;	—

Countries

China

Contacts

Public ContactXianbo Wang

Beijing Ditan Hospital Capital Medical University

wangxb@ccmu.edu.cn+86 10 8432 2586

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026